We're working on something new at CrunchBase. Edits have been disabled for a few days, but you can still contact us for urgent changes.
Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information

Funds

Abingworth Bioventures VI, 2/2014 £225M

Offices

Headquarters
38 Jermyn Street
London, SW1Y 6DN, GBR
Menlo Park Office
3000 Sand Hill Road
B1-145
Menlo Park, CA, 94025
USA
Abingworth Office
890 Winter Street
Suite 150
Waltham, MA, 02451
USA

People

Managing Partner
Partner
Partner
Partner and CFO
Partner
Partner
Venture Partner
Executive Partner and General Counsel
Show All People

Tags

Abingworth

Abingworth is an international investment group dedicated exclusively to the life sciences and healthcare sectors. We invest across all stages of company development including early and late-stage venture financing, growth equity and public companies.

Founded in 1973, Abingworth has a lengthy track record of building market leading companies. Our specialist team of over 20 professionals has a broad range of skills, including scientific and business expertise as well as investment banking, recruitment and legal knowledge. These resources are made available to portfolio companies. Abingworth has funds under management of over $1.25 billion and offices in London, Menlo Park (California) and Boston.

Recent Milestones

Investments

Company Date Round Size Participants
Wilson Therapeutics 4/2014Series B$40M2
Pixium Vision 11/2013Series A€15M5
Personalis 10/2013Series B$22M3
Dicerna Pharmaceuticals 7/2013Series C$60M9
Effector Therapeutics 5/2013Venture Round$45M7
GenSight Biologics 4/2013Series A€32M4
Gynesonics 2/2013Debt$22.2M5
Avillion 1/2013Venture Round2
Labcyte 1/2013Series D$5.3M7
Chiasma 7/2012Series D$38.5M3
Sonitus Technologies 5/2012Venture Round$34.4k4
Sonitus Medical 5/2012Series D$25M7
Prosensa 1/2012Venture Round€23M7
Valeritas 9/2011Series C$150M8
MD On-Line 5/2011Venture Round$12M1
Syntaxin 11/2010Series C$29M7
IS Pharma 10/2010Venture Round$5.7M1
Pathwork Diagnostics 10/2010Series C$30M6
Oxagen 11/2009Series C$26.7M9
PrimeraDx (Primera Biosystems) 10/2009Series C$20M6
Zogenix 10/2009Series B$36M5
Intellikine 7/2009Series B$51M6
Chroma Therapeutics 6/2009Venture Round$24.5M6
Clovis Oncology 5/2009Private Equity$145M7
Synosia Therapeutics 1/2009Series B$29M7
Broncus Technologies, Inc. 7/2008Debt3
Zogenix 1/2008Venture Round$18M4
Syntaxin 10/2007Series B$32M5
Synosia Therapeutics 1/2007Venture Round$32.5M4
Chroma Therapeutics 4/2006Series C$53M5
Syntaxin 11/2005Series A$10.4M1
Adiana 8/2005Series D$23M9

Videos

Sources

  1. Abingworth Exceeds Target for Bioventure Fund (pevc.dowjones.com) [edit]
  2. Wilson Therapeutics Receives $40M in Series B Funding (finsmes.com) [edit]
  3. Pixium Vision Raises €15M in Series A Financing (finsmes.com) [edit]
  4. Personalis Closes $22M Series B Financing (finsmes.com) [edit]
  5. Dicerna Pharmaceuticals Raises $60M In Series C Financing (finsmes.com) [edit]
  6. Effector Therapeutics snags $45M venture round from A-list backers (fiercebiotech.com) [edit]
  7. GenSight Biologics Raises €32m in a Series A Financing for Ophthalmic Gene Therapy (finance.yahoo.com) [edit]
  8. SEC (sec.gov) [edit]
  9. Avillion Receives Funding from Abingworth and Clarus Ventures (finsmes.com) [edit]
  10. Labcyte Closes $5.3M Series D Financing (finsmes.com) [edit]
  11. Chiasma Closes $38.5M Series D Equity Financing (finsmes.com) [edit]
  12. SEC (sec.gov) [edit]
  13. Sonitus Medical Closes $25 Million Series D Round of Venture Capital Financing (sonitusmedical.com) [edit]
  14. Prosensa Raises €23 Million in New Equity Financing Led by New Enterprise Associates (reuters.com) [edit]
  15. Valeritas Raises $150m in Series C financing. (finsmes.com) [edit]
  16. SEC (sec.gov) [edit]
  17. VCs inject $29M into Syntaxin, $11.5M into Ceregene (fiercebiotech.com) [edit]
  18. Public IS Pharma Takes In $5.7M From Abingworth In Private Placement (fis.dowjones.com) [edit]
  19. Alta Partners Leads $30M Series C For Pathwork Diagnostics (fis.dowjones.com) [edit]
  20. Oxagen rounds up $26.7M in VC (fiercebiotech.com) [edit]
  21. PrimeraDx, Inc.: Series C $20M (onbiovc.com) [edit]
  22. SEC D (sec.gov) [edit]
  23. Intellikine, Inc.: Series B $51M (onbiovc.com) [edit]
  24. Capital Report Index [edit]
  25. Clovis Oncology (Boulder, CO) an entity focused on licensing or acquiring rights to oncology compounds in all stages of clinical development (onbiovc.com) [edit]
  26. Synosia raises $29M for Phase II testing (fiercebiotech.com) [edit]
  27. Broncus Technologies lines up venture debt financing for emphysema treatment (venturebeat.com) [edit]
  28. Zogenix Raises $18 Million in Preferred Stock Financing (zogenix.com) [edit]
  29. Syntaxin Raises $32M to Advance Development of Novel Drug Pipeline (syntaxin.com) [edit]
  30. Neurological co. Synosis raises $32.5M (venturebeat.com) [edit]
  31. CHROMA THERAPEUTICS COMPLETES $53 MILLION SERIES C FINANCING (chromatherapeutics.com) [edit]
  32. EDGAR [edit]
  33. Adiana, Inc. Reports Completion of $23 Million Financing. (allbusiness.com) [edit]
Edit This Page
Last Edited 4/17/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy